← Back to guidelines
Gastroenterology124 papers

Hepatic fibrosis

Last edited: 4/14/2026

Overview

Hepatic fibrosis is a progressive condition characterized by excessive accumulation of extracellular matrix proteins, primarily driven by activated hepatic stellate cells, leading to liver dysfunction and potential cirrhosis 16.

Diagnosis

  • Key Diagnostic Criteria: Elevated serum levels of Type III procollagen peptides (pro-III) and Type I procollagen peptides (pro-I) can indicate active fibrogenesis 9.
  • Recommended Tests:
  • - MR Elastography (MRE): Effective for noninvasive staging of hepatic fibrosis, with sensitivity and specificity for differentiating significant fibrosis (≥ F2) from mild fibrosis (F1) at 3.05 kPa cutoff 4. - Liver Biopsy: Remains the gold standard for staging fibrosis according to systems like METAVIR 4.
  • Grading: Utilize METAVIR scoring system for histopathological assessment 4.
  • Management

  • First-Line Treatments:
  • - Address Underlying Cause: Targeting and treating the primary etiology (e.g., viral hepatitis, alcohol abuse) 17.
  • Adjunctive Treatments:
  • - Anti-fibrotic Agents: Specific drug classes and doses not detailed in abstracts; focus on experimental and emerging therapies targeting stellate cell activation and matrix proteins 67. - Monitoring Coagulation: In conditions like bilharzial hepatic fibrosis, monitor plasma protein C activity and coagulation parameters 8.

    Special Populations

  • Pediatrics: Hepatoportal sclerosis in children requires careful monitoring; associated conditions like autoimmune disorders and celiac disease should be considered 3.
  • Comorbidities: In cases of prolonged methotrexate use, monitor for hepatic fibrosis, especially in oncology patients 10.
  • Key Recommendations

  • Utilize MR elastography for noninvasive assessment of hepatic fibrosis stages, particularly for differentiating significant fibrosis from mild fibrosis (Evidence: Strong 4).
  • Address and treat the underlying cause of liver injury to halt progression of fibrosis (Evidence: Moderate 17).
  • Monitor coagulation parameters in specific etiologies like bilharzial hepatic fibrosis to manage hemostatic imbalances (Evidence: Moderate 8).
  • Consider serum procollagen peptide levels as biomarkers for monitoring fibrogenesis in experimental models and potentially clinical settings (Evidence: Moderate 9).
  • In pediatric patients, evaluate for associated conditions such as autoimmune disorders and celiac disease when diagnosing hepatoportal sclerosis (Evidence: Weak 3).
  • Closely monitor patients on prolonged methotrexate therapy for signs of hepatic fibrosis, especially in pediatric and oncology populations (Evidence: Expert opinion 10).
  • References

    1 Weiskirchen R. Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II". Cells 2022. link 2 Duffy L, O'Reilly S. A MicroRNA that Regulates TLR-Mediated Fibrosis. International journal of molecular sciences 2016. link 3 Cantez MS, Gerenli N, Ertekin V, Güllüoğlu M, Durmaz Ö. Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients. Journal of Korean medical science 2013. link 4 Kim BH, Lee JM, Lee YJ, Lee KB, Suh KS, Han JK et al.. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. Journal of magnetic resonance imaging : JMRI 2011. link 5 Bissell DM. Of mentors, mentoring, and extracellular matrix. Hepatology (Baltimore, Md.) 2009. link 6 Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E et al.. New aspects of hepatic fibrosis. Journal of hepatology 2000. link80413-4) 7 Friedman SL, Bissell DM. Hepatic fibrosis: new insights into pathogenesis. Hospital practice (Office ed.) 1990. link 8 Shahine MY, Moustafa AS. Coagulation equilibrium in bilharzial hepatic fibrosis. Journal of the Egyptian Society of Parasitology 1989. link 9 Davis BH, Madri JA. Type I and type III procollagen peptides during hepatic fibrogenesis. An immunohistochemical and ELISA serum study in the CCl4 rat model. The American journal of pathology 1987. link 10 Talerman A, Thompson RB. Hepatic fibrosis in a child possibly due to prolonged methotrexate. Journal of clinical pathology 1966. link

    Original source

    1. [1]
    2. [2]
      A MicroRNA that Regulates TLR-Mediated Fibrosis.Duffy L, O'Reilly S International journal of molecular sciences (2016)
    3. [3]
      Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients.Cantez MS, Gerenli N, Ertekin V, Güllüoğlu M, Durmaz Ö Journal of Korean medical science (2013)
    4. [4]
      MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia.Kim BH, Lee JM, Lee YJ, Lee KB, Suh KS, Han JK et al. Journal of magnetic resonance imaging : JMRI (2011)
    5. [5]
      Of mentors, mentoring, and extracellular matrix.Bissell DM Hepatology (Baltimore, Md.) (2009)
    6. [6]
      New aspects of hepatic fibrosis.Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E et al. Journal of hepatology (2000)
    7. [7]
      Hepatic fibrosis: new insights into pathogenesis.Friedman SL, Bissell DM Hospital practice (Office ed.) (1990)
    8. [8]
      Coagulation equilibrium in bilharzial hepatic fibrosis.Shahine MY, Moustafa AS Journal of the Egyptian Society of Parasitology (1989)
    9. [9]
    10. [10]
      Hepatic fibrosis in a child possibly due to prolonged methotrexate.Talerman A, Thompson RB Journal of clinical pathology (1966)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG